Background: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. Objectives: This Phase 1, single-blind, multiple dose, drug-drug interaction (DDI) study evaluated the pharmacokinetics (PK), pharmacodynamics, and tolerability of verinurad in combination with febuxostat (FBX) in healthy male volunteers. Methods: Subjects were randomized to receive once-daily doses of FBX or verinurad or placebo alone for 7 days, FBX + verinurad or FBX + placebo on days 8-14, and the alternative single agent (FBX or verinurad or placebo) on days 15-21. Subjects received either the combination of verinurad 10 mg + FBX 40 mg or verinurad 2.5 mg + FBX 80 mg. Serial plasma/serum and urine samples were drawn at predetermined time points on Days 7, 14 and 21, and assayed for verinurad, FBX, and uric acid. Baseline samples were drawn on Day −1. Safety was assessed by adverse event (AE) reports, laboratory tests, vital signs, and electrocardiograms (ECGs). Results: Of 23 randomized subjects, 20 completed the study. FBX 40 mg had no apparent effect on the plasma C max and AUC for verinurad 10 mg, whereas FBX 80 mg increased the plasma C max and AUC for verinurad 2.5 mg by 25% and 33%, respectively. Verinurad had no effect on FBX PK. Renal clearance of verinurad was unchanged by FBX. The mean maximal reduction in serum uric acid (sUA) was 76% with verinurad 10 mg + FBX 40 mg compared with verinurad 10 mg (56%) or FBX 40 mg (49%) alone ( Figure 1A ) and was 67% with verinurad 2.5 mg + FBX 80 mg compared with verinurad 2.5 mg (38%) or FBX 80 mg (57%) alone ( Figure 1B) . Consistent with the mechanism of action (MOA) of verinurad, 24-hr fractional excretion of uric acid (FEUA) increased (2.5 mg: 7.6%; 10 mg: 12.8%) vs baseline (6.5% and 6.0%, respectively). Renal clearance of uric acid (CL UR ) increased similarly (2.5 mg: 9.0 mL/min; 10 mg: 12.3 mL/min) vs baseline (8.3 and 7.3 mL/min, respectively). The increases were maintained for 24 hours with verinurad 10 mg + FBX 40 mg (FEUA: 11.8%; CL UR : 13.6mL/min). Consistent with its MOA, FBX 40 mg and 80 mg decreased the amount of uric acid excreted in urine (246 and 221 mg, respectively, vs baseline: 695 and 818 mg), FEUA (4.79 and 4.18%, respectively, vs baseline: 6.31 and 6.54%), and CL UR (4.91 and 4.96 mL/min, respectively, vs baseline: 7.71 and 8.73 mL/min). No serious AEs, discontinuations due to AEs, or clinically significant laboratory or ECG abnormalities were noted during the study.
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Background: Large scale randomized studies are underway to assess whether compared to placebo, each XO-inhibitor, allopurinol or febuxostat, can prevent renal function loss. This evidence is needed and will confirm their nephroprotective potential. However, neither study will answer a key question: Does the renal protective effect of allopurinol differ from that of febuxostat? Objectives: To assess the comparative effectiveness of allopurinol vs. febuxostat for preventing incident renal disease in elderly. Methods: In a retrospective cohort study using Medicare claims data, we included patients newly treated with allopurinol or febuxostat (baseline period of 183 days without either medication). We used 1:5 propensity-matched Cox regression analyses to compare the hazard ratio (HR) of incident renal disease with allopurinol use and allopurinol dose vs. febuxostat (reference category). Sensitivity analyses included multivariable-adjusted regression models. Background: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. Objectives: This Phase 1, single-blind, multiple dose, drug-drug interaction study evaluated the pharmacokinetics (PK), pharmacodynamics, and tolerability of verinurad in combination with allopurinol (ALLO) in adult male subjects with gout. Methods: Adult males with gout, aged 18-75 years, with serum uric acid (sUA) ≥8 mg/dL were randomized to receive once-daily oral doses of ALLO 300 mg or verinurad 10 mg alone for 7 days, ALLO 300 mg + verinurad 10 mg on Days 8-14, and the alternative single agent (verinurad 10 mg or ALLO 300 mg) on Days 15-21. Colchicine 0.6 mg was taken once daily from day −14. Serial plasma/serum and urine samples were drawn at predetermined time points on Days 7, 14 and 21 and assayed for verinurad, ALLO, oxypurinol (OXY), colchicine, and uric acid. Baseline samples were drawn on Day -1. Safety was assessed by adverse event (AE) reports, laboratory tests, vital signs, and electrocardiograms (ECGs). Results: Subjects (N=12) were mostly white (58.3%) with mean (SD) age of 51 (10) years. Following multiple doses, ALLO had no effect on C max and AUC of verinurad. ALLO C max was increased 33% but AUC was unaltered by verinurad. The C max and AUC for OXY, the active metabolite of ALLO, were reduced 32% and 38%, respectively, by verinurad. Colchicine plasma exposures were unaltered by verinurad. ALLO had no effect on urinary excretion of verinurad, whereas urinary excretion of OXY was increased 19% by verinurad. The mean maximal decrease in sUA was 65% with verinurad + ALLO compared with verinurad (51%) or ALLO (43%) alone ( Figure) . Consistent with the mechanism of action (MOA) of verinurad, 24-h fractional excretion of uric acid (FEUA) and clearance of uric acid (CL UR ) were increased in the absence (9.2% and 11.5 mL/min, respectively) or presence of ALLO (7.9% and 11.8 mL/min) vs baseline (4.5% and 5.7 mL/min) or ALLO alone (3.7% and 5.0 mL/min). Consistent with its MOA, ALLO decreased the amount of uric acid excreted in 24-h urine (363 mg) compared with baseline (683 mg), verinurad alone (739 mg) or verinurad + ALLO (522 mg) but had no effect on FEUA or CL UR . No serious AEs, discontinuations due to AEs, or clinically significant laboratory or ECG abnormalities were noted.
Conclusions:
Although a modest drug-drug interaction was found between verinurad and ALLO, the combination was safe and well tolerated at the studied doses and resulted in greater reduction of sUA than either alone. These results support the evaluation of verinurad + ALLO as an alternative once-daily treatment option for hyperuricemia and gout. Background: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. Objectives: This Phase 1, single-dose, open-label study investigated the pharmacodynamics (PD), pharmacokinetics (PK), and safety of oral verinurad in adult subjects with mild, moderate, or severe renal impairment and matched controls with normal renal function (NCT02219516). Methods: Adult males aged 18-85 years were enrolled with a screening serum uric acid (sUA) 4.5-10 mg/dL and creatinine clearance calculated by CockcroftGault formula of 60 to <90 mL/min (mild renal impairment), 30 to <60 mL/min (moderate impairment), 15 to <30 mL/min (severe impairment), or ≥90 mL/min (matched controls). Oral verinurad 15 mg was administered once under fasted conditions. Serial blood and urine samples were taken 30 min before and up to 72 hours postdose. Safety assessments included laboratory, ECG, and vital sign parameters as well as adverse event (AEs) reporting. Results: PD data were based on 7-8 subjects per group. Verinurad decreased sUA in all groups, with greatest changes in the normal function and mild renal impairment groups. Mean (SD) maximal % change in sUA from baseline (Emax) was -38.3 (14.8)%, -36.9 (13.6)%, -20.5 (6.64)%, and -12.6 (6.94)%, respectively, in the normal function and mild, moderate, and severe renal impairment groups. Increase in the amount of excretion of uric acid due to verinurad treatment decreased in subjects with moderate and severe renal impairment. Plasma Cmax and AUC of verinurad increased with decreasing renal function. Verinurad at the 15 mg dose was well tolerated, with no serious AEs, no subject withdrawals due to AEs, and no Renal Events Adjudication Committee (REAC)-adjudicated renal events during treatment. One patient in each renal impairment group had treatment-emergent AEs considered possibly related to verinurad, which were categorized as gastrointestinal in nature. There were no clinically meaningful changes noted in laboratory values or vital signs.
The sUA lowering effect of verinurad was observed across the spectrum of renal function. Consistent with the verinurad renal-dependent mechanism of action, decreasing sUA lowering was demonstrated with increasing renal impairment. Verinurad safety and tolerability were similar across all stages of renal impairment. Background: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. Objectives: This Phase 2a, randomized, open-label, multicenter study investigated the multiple-dose pharmacodynamics (PD), pharmacokinetics (PK), and safety of oral verinurad in combination with febuxostat versus febuxostat alone in adults with gout (NCT02246673). Methods: Patients aged ≥18 and ≤75 years with gout and serum uric acid (sUA) ≥8 mg/dL were randomized to 1 of 5 cohorts to receive febuxostat (40 mg and 80 mg) alone and in combination with verinurad (dose range 2.5 mg to 20 mg; 4 treatment periods per cohort, each treatment period 7 days). Medications were administered once daily ∼30 min after breakfast. Colchicine 0.6 mg for gout flare prophylaxis was initiated at approximately Day -14 (start of urate-lowering therapy [ULT]) washout) or Day -7 if not on ULT. Serial blood and urine samples were measured at preset intervals on Days -1, 1, 7, 14, 21, and 28 for PD and PK endpoints. Safety assessments included adverse events (AEs) and laboratory, electrocardiograms, and vital sign parameters. Results: Sixty-four patients were randomized (n=12-14 per cohort). Serum PD data pooled across cohorts demonstrated maximal % decrease in sUA from baseline (Emax) at 8-12 h after dosing. Addition of verinurad to febuxostat decreased sUA in dose-dependent manner (Figure 1 ). Greater sUA reductions were observed for dose combinations of verinurad ≥5 mg with febuxostat 40 mg versus febuxostat 80 mg alone. The rate of urinary uric acid excretion was reduced by febuxostat alone, but comparable to baseline levels with verinurad combined with febuxostat. Verinurad plasma exposures increased with verinurad dose and were comparable for febuxostat 40 mg and 80 mg doses. No drug-drug interaction on verinurad and febuxostat plasma PK parameters was observed. Verinurad at doses from 2.5 mg to 20 mg was well tolerated, with no serious AEs, withdrawals due to AEs, or renal-related events. The most frequent treatment-emergent AE possibly related to study medication was pain in extremity, in 2 patients receiving verinurad. Laboratory values and vital signs showed no clinically meaningful changes. There were no cases of serum creatinine elevation ≥1.5x baseline.
Verinurad coadministered with febuxostat dose-dependently decreased sUA while maintaining urine uric acid levels comparable to baseline. All dose combinations of verinurad and febuxostat in this study were generally well tolerated with no serious AEs or renal-related events during combination treatment. Background: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia.
